WO2006100082A3 - Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung - Google Patents

Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung Download PDF

Info

Publication number
WO2006100082A3
WO2006100082A3 PCT/EP2006/002685 EP2006002685W WO2006100082A3 WO 2006100082 A3 WO2006100082 A3 WO 2006100082A3 EP 2006002685 W EP2006002685 W EP 2006002685W WO 2006100082 A3 WO2006100082 A3 WO 2006100082A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
drugs containing
oxindol
substituted
substituted oxindol
Prior art date
Application number
PCT/EP2006/002685
Other languages
English (en)
French (fr)
Other versions
WO2006100082A2 (de
Inventor
Thorsten Oost
Wilfried Lubisch
Wolfgang Wernet
Wilfried Hornberger
Liliane Unger
Original Assignee
Abbott Gmbh & Co Kg
Thorsten Oost
Wilfried Lubisch
Wolfgang Wernet
Wilfried Hornberger
Liliane Unger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200510014628 external-priority patent/DE102005014628A1/de
Priority claimed from DE200510015957 external-priority patent/DE102005015957A1/de
Application filed by Abbott Gmbh & Co Kg, Thorsten Oost, Wilfried Lubisch, Wolfgang Wernet, Wilfried Hornberger, Liliane Unger filed Critical Abbott Gmbh & Co Kg
Priority to MX2007011693A priority Critical patent/MX2007011693A/es
Priority to US11/886,730 priority patent/US7803834B2/en
Priority to CA002602194A priority patent/CA2602194A1/en
Priority to JP2008502331A priority patent/JP2008534461A/ja
Priority to EP06723672A priority patent/EP1861392A2/de
Publication of WO2006100082A2 publication Critical patent/WO2006100082A2/de
Publication of WO2006100082A3 publication Critical patent/WO2006100082A3/de
Priority to US12/847,529 priority patent/US8691815B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Die vorliegende Erfindung betrifft neue Oxindol-Derivate der allgemeinen Formel (I), worin die Substituenten R1, R2, A, B und Y wie in Anspruch 1 definiert sind, diese enthaltende Arzneimittel und deren Verwendung zur Prophylaxe und/oder Behandlung von Vasopressin-abhängigen und/oder Oxytocin-abhängigen Krankheiten.
PCT/EP2006/002685 2005-03-24 2006-03-23 Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung WO2006100082A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX2007011693A MX2007011693A (es) 2005-03-24 2006-03-23 Derivados de oxindoles sustituidos, farmacos que contienen dichos derivados y uso de los mismos.
US11/886,730 US7803834B2 (en) 2005-03-24 2006-03-23 Substituted oxindole derivatives, drugs containing said derivatives and the use thereof
CA002602194A CA2602194A1 (en) 2005-03-24 2006-03-23 Substituted oxindol derivatives, drugs containing said derivatives and the use thereof
JP2008502331A JP2008534461A (ja) 2005-03-24 2006-03-23 置換オキシインドール誘導体、前記誘導体を含む医薬およびそれの使用
EP06723672A EP1861392A2 (de) 2005-03-24 2006-03-23 Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
US12/847,529 US8691815B2 (en) 2005-03-24 2010-07-30 Substituted oxindole derivatives, drugs containing said derivatives and the use thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US66475905P 2005-03-24 2005-03-24
US60/664,759 2005-03-24
DE200510014628 DE102005014628A1 (de) 2005-03-26 2005-03-26 Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102005014628.7 2005-03-26
DE102005015957.5 2005-03-31
DE200510015957 DE102005015957A1 (de) 2005-03-31 2005-03-31 Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/886,730 A-371-Of-International US7803834B2 (en) 2005-03-24 2006-03-23 Substituted oxindole derivatives, drugs containing said derivatives and the use thereof
US12/847,529 Division US8691815B2 (en) 2005-03-24 2010-07-30 Substituted oxindole derivatives, drugs containing said derivatives and the use thereof

Publications (2)

Publication Number Publication Date
WO2006100082A2 WO2006100082A2 (de) 2006-09-28
WO2006100082A3 true WO2006100082A3 (de) 2006-12-07

Family

ID=36843280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/002685 WO2006100082A2 (de) 2005-03-24 2006-03-23 Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung

Country Status (6)

Country Link
US (2) US7803834B2 (de)
EP (1) EP1861392A2 (de)
JP (1) JP2008534461A (de)
CA (1) CA2602194A1 (de)
MX (1) MX2007011693A (de)
WO (1) WO2006100082A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) * 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8044079B2 (en) * 2005-12-02 2011-10-25 Abbott Gmbh & Co. Kg Substituted oxindole derivatives, medicaments containing said derivatives and use thereof
GB0526051D0 (en) 2005-12-21 2006-02-01 Oxford Biosensors Ltd Cholesterol sensor
FR2909668B1 (fr) * 2006-12-12 2009-01-23 Sanofi Aventis Sa Derives de 5-alkyloxy-indolin-2-one,leur preparation et leurs applications en therapeutique
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
WO2008080971A1 (en) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Substituted oxindole derivative and its use as a vasopressin receptor ligand
WO2008080972A1 (en) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Substituted oxindole derivative and its use as a vasopressin receptor modulator
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
ES2401908T3 (es) * 2006-12-30 2013-04-25 Abbott Gmbh & Co. Kg Derivado de oxindol sustituido y su uso como ligando del receptor de vasopresina
WO2008107399A1 (en) * 2007-03-02 2008-09-12 Abbott Gmbh & Co. Kg Substituted oxindole compounds
WO2009071687A1 (de) 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg Amidomethyl-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
CA2707669C (en) * 2007-12-07 2016-07-05 Wilfried Braje 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
CA2707671C (en) 2007-12-07 2016-02-02 Abbott Gmbh & Co. Kg 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
FR2927625B1 (fr) 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
MX346799B (es) 2010-12-21 2017-03-31 Bayer Ip Gmbh Metodo para la produccion de oxindoles sustituidos en el n con sulfonilo.
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018105A1 (fr) * 1993-12-24 1995-07-06 Sanofi Derives de 1,3-dihydroindol-2-one substitues en 3 par un groupe azote comme agonistes et/ou antagonistes de la vasopressine et/ou de l'ocytocine
WO2001055130A2 (fr) * 2000-01-25 2001-08-02 Sanofi-Synthelabo Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b ou v1b et v1a de l'arginine-vasopressine
WO2001055134A2 (fr) * 2000-01-25 2001-08-02 Sanofi-Synthelabo Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands pour les recepteurs v1b ou v1b et v1a de l'arginine-vasopressine
WO2001098295A1 (fr) * 2000-06-19 2001-12-27 Sanofi-Synthelabo Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b et v1a de l'arginine-vasopressine
WO2005030755A1 (en) * 2003-09-30 2005-04-07 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
WO2006072458A2 (de) * 2004-12-31 2006-07-13 Abbott Gmbh & Co. Kg Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2805536B1 (fr) 2000-02-25 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
EP1659121A4 (de) * 2003-08-28 2008-11-26 Taisho Pharmaceutical Co Ltd 1,3-dihydro-2h-indol-2-onderivat
JP5125501B2 (ja) * 2005-01-28 2013-01-23 大正製薬株式会社 １，３−ジヒドロ−２ｈ−インドール−２−オン化合物、及び芳香族複素環が縮合したピロリジン−２−オン化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018105A1 (fr) * 1993-12-24 1995-07-06 Sanofi Derives de 1,3-dihydroindol-2-one substitues en 3 par un groupe azote comme agonistes et/ou antagonistes de la vasopressine et/ou de l'ocytocine
WO2001055130A2 (fr) * 2000-01-25 2001-08-02 Sanofi-Synthelabo Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b ou v1b et v1a de l'arginine-vasopressine
WO2001055134A2 (fr) * 2000-01-25 2001-08-02 Sanofi-Synthelabo Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands pour les recepteurs v1b ou v1b et v1a de l'arginine-vasopressine
WO2001098295A1 (fr) * 2000-06-19 2001-12-27 Sanofi-Synthelabo Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b et v1a de l'arginine-vasopressine
WO2005030755A1 (en) * 2003-09-30 2005-04-07 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
WO2006072458A2 (de) * 2004-12-31 2006-07-13 Abbott Gmbh & Co. Kg Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung

Also Published As

Publication number Publication date
EP1861392A2 (de) 2007-12-05
US7803834B2 (en) 2010-09-28
CA2602194A1 (en) 2006-09-28
WO2006100082A2 (de) 2006-09-28
JP2008534461A (ja) 2008-08-28
MX2007011693A (es) 2008-03-11
US20090163492A1 (en) 2009-06-25
US20110071132A1 (en) 2011-03-24
US8691815B2 (en) 2014-04-08

Similar Documents

Publication Publication Date Title
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
WO2007140385A3 (en) Thiazole compounds as cannabinoid receptor ligands and uses thereof
WO2008110355A8 (en) Quinoline derivatives as fungicides
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2009046841A8 (de) Piperidin- und piperazinderivate zur behandlung von tumoren
WO2006058700A8 (en) Acetamide compounds as fungicides
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2007061360A3 (en) Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides
WO2009087098A3 (en) Quinoline derivatives and their use as fungicides
IL188606A0 (en) Novel 1,4-benzothiazepine-1,1-dioxide, derivative having improved properties, method for the production thereof, medicaments containing said compound, and use thereof
MX2007006397A (es) Derivados de tetrahidropirano.
WO2006103277A3 (en) 2 , 4 , 5-substituted piperidines as renin inhibitors
WO2007061923A3 (en) Glucokinase activators
WO2007084595A3 (en) Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
WO2006072458A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
WO2007065595A3 (en) Xanthine derivatives, processes for preparing them and their uses
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
TW200700358A (en) Organic compounds
TW200745039A (en) Isotopically substituted pantoprazole
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
WO2009030467A3 (en) Saturated and insaturated bi- or tricyclic aryloxyacetamide derivatives and their use as fungicides
WO2007020261A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2602194

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/011693

Country of ref document: MX

Ref document number: 2008502331

Country of ref document: JP

Ref document number: 2006723672

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWP Wipo information: published in national office

Ref document number: 2006723672

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11886730

Country of ref document: US